Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's Jubilant Completes Acquisition of U.S. Co Hollister-Stier (India)

This article was originally published in PharmAsia News

Executive Summary

Jubilant Organosys, a pharmaceutical research company in India, has finalized the purchase of U.S.-based Hollister-Stier Laboratories for $122.5 million in an all-cash transaction. Jubilant is looking to strengthen its growing global expertise in custom-research and manufacturing services. (Click here for more

You may also be interested in...



Jubilant Profits Spurred By Foreign Business

Buoyed chiefly by earnings from its foreign businesses, India's pharmaceuticals and chemicals major Jubilant Organosys reported a net profit of 4 billion rupees ($98 million) for the year ending March 31

India’s Jubilant Organosys Nets $92 Million CRAMS Order For 2008

NEW DELHI - India's growing success in the pharmaceutical custom research and manufacturing services sector is demonstrated by Jubilant Organosys netting CRAMS contracts totaling $92 million for 2008, with most contracts coming from Japan, China, the U.S. and Europe, the Uttar Pradesh-based manufacturer said Feb. 2

Keeping Track: Tauvid, Oriahnn, Artesunate Clear US FDA, Along With Trio Of Pediatric Approvals

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

UsernamePublicRestriction

Register

WI964856

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel